RXi, Calif. Firm In Skin Treatment Collaboration
RXi Pharmaceuticals Corp. of Worcester will collaborate with TransDerm Inc. to study the potential for RXi technology to be used in dermatology.
California-based TransDerm is developing drugs and drug delivery systems for the treatment of skin disorders.
The partnership ensures "the rapid progression of our compounds into clinical development," RXi said. The company recently released pre-clinical data on the performance of one of its RNA compounds on "compromised skin."
TransDerm was recently awarded a National Institutes of Health grant to compare existing skin drug delivery systems.
The company is also developing an RNAi-based skin disorder drug.
RNAi, which was discovered by RXi co-founder and University of Massachusetts Medical School professor Craig Mello, seeks to treat diseases by interfering with the genes thought to cause those diseases.
WBJ Web Partners
Most Recent
Most Recent
0 Comments